Gemfibrozil and Lamisil drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Gemfibrozil (gemfibrozil) and Lamisil (terbinafine hydrochloride). Common drug interactions include intervertebral disc protrusion among females and kidney infection among males.

The phase IV clinical study analyzes what interactions people have when they take Gemfibrozil and Lamisil. It is created by eHealthMe based on reports of 17 people who take the same drugs from the FDA, and is updated regularly.

What is Gemfibrozil?

Gemfibrozil has active ingredients of gemfibrozil. It is often used in high blood cholesterol. eHealthMe is studying from 18,213 Gemfibrozil users. Check the latest studies of Gemfibrozil.

What is Lamisil?

Lamisil has active ingredients of terbinafine hydrochloride. It is often used in pulmonary aspergilloma (mycetoma). eHealthMe is studying from 14,080 Lamisil users. Check the latest studies of Lamisil.



On Jul, 10, 2026

17 people who take Gemfibrozil and Lamisil together, and have interactions are studied.

Gemfibrozil and Lamisil drug interactions.

What are the common drug interactions of Gemfibrozil and Lamisil, by gender? *:

female:

  1. Intervertebral disc protrusion (spinal disc protrusion)
  2. Irritable bowel syndrome
  3. Judgement impaired
  4. Labyrinthitis (inflammation of the labyrinth or inner ear)
  5. Lichen planus (an inflammatory skin condition, characterized by an itchy, non-infectious rash)
  6. Lip injury
  7. Kidney infection
  8. Overdose
  9. Respiratory arrest (cessation of normal respiration due to failure of the lungs to function effectively)
  10. Unresponsive to stimuli

male:

  1. Kidney infection
  2. Respiratory arrest (cessation of normal respiration due to failure of the lungs to function effectively)
  3. Dry mouth
  4. Eye irritation
  5. Loss of consciousness
  6. Oedema peripheral (superficial swelling)
  7. Pruritus (severe itching of the skin)
  8. Urticaria (rash of round, red welts on the skin that itch intensely)
  9. Overdose
  10. Unresponsive to stimuli

What are the common drug interactions of Gemfibrozil and Lamisil, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Conjunctivitis (pink eye)
  2. Dermatitis (inflammation of the skin resulting from direct irritation by an external agent or an allergic reaction to it)
  3. Dry mouth
  4. Oedema peripheral (superficial swelling)
  5. Pruritus (severe itching of the skin)

50-59:

  1. Nail disorder (disease of nail)
  2. Anosmia (partial or complete loss of the sense of smell)
  3. Chronic kidney disease
  4. Hyperparathyroidism secondary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-secondary)
  5. Nephrogenic anaemia (anaemia due to kidney disease)
  6. Renal failure (kidney dysfunction)
  7. Drug ineffective

60+:

  1. Memory impairment
  2. Muscular weakness (muscle weakness)
  3. Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
  4. Bruxism (habitual grinding of the teeth, typically during sleep)
  5. Burning sensation
  6. Butterfly rash
  7. Cataract (clouding of the lens inside the eye)
  8. Chest pain
  9. Choking (mechanical obstruction of the flow of air from the environment into the lungs)
  10. Chorea (abnormal involuntary movement disorder)

What are the existing conditions these people have? *

  1. High Blood Pressure: 4 people, 23.53%
  2. Pain: 4 people, 23.53%
  3. Depression: 4 people, 23.53%
  4. Fungal Nail Infection: 4 people, 23.53%
  5. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 4 people, 23.53%
  6. Coronary Heart Disease (narrowing or blockage of the coronary arteries): 3 people, 17.65%
  7. Diabetes: 3 people, 17.65%
  8. Hyperlipidaemia (presence of excess lipids in the blood): 3 people, 17.65%
  9. Constipation: 2 people, 11.76%
  10. Multiple Myeloma (cancer of the plasma cells): 2 people, 11.76%

* Approximation only. Some reports may have incomplete information.

Do you take Gemfibrozil and Lamisil?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Gemfibrozil and Lamisil:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Gemfibrozil:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Lamisil:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Gemfibrozil and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Lamisil and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on gemfibrozil and terbinafine hydrochloride (the active ingredients of Gemfibrozil and Lamisil, respectively), and Gemfibrozil and Lamisil (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: